Handelsbanken Fonder AB Acquires 4,403 Shares of argenx SE (NASDAQ:ARGX)

Handelsbanken Fonder AB lifted its position in argenx SE (NASDAQ:ARGX - Free Report) by 13.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,050 shares of the company's stock after buying an additional 4,403 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.06% of argenx worth $22,520,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GeoWealth Management LLC lifted its stake in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after purchasing an additional 18 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in argenx in the 4th quarter worth approximately $37,000. Global Retirement Partners LLC increased its holdings in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the last quarter. FIL Ltd purchased a new stake in shares of argenx during the 4th quarter valued at $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of argenx during the 4th quarter worth $38,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ARGX shares. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. William Blair reissued an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Guggenheim reduced their price objective on argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. JMP Securities set a $699.00 target price on argenx in a report on Wednesday, May 14th. Finally, Wells Fargo & Company lifted their price target on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $709.18.

argenx Trading Up 1.5%

NASDAQ:ARGX traded up $8.88 during trading hours on Thursday, reaching $583.84. 93,159 shares of the company traded hands, compared to its average volume of 323,113. argenx SE has a 1 year low of $376.59 and a 1 year high of $678.21. The stock has a market capitalization of $35.65 billion, a P/E ratio of -663.45 and a beta of 0.39. The business's 50-day moving average price is $586.20 and its two-hundred day moving average price is $611.99.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities analysts anticipate that argenx SE will post 3.13 EPS for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.